Redox-regulated adaptive pathways in heart failure (renewal)

Heart failure patients have no treatment that helps their hearts adapt to the overload—only drugs that slow the damage. This programme targets that gap. The problem: when the heart is chronically overworked, it remodels. Some of that remodelling is harmful, some is adaptive and protective. Current therapies (ACE inhibitors, beta-blockers) only curb the harmful side, with modest results. No drug exists to boost the heart’s own adaptive response. The researchers have discovered that a protein called NOX4, which generates reactive oxygen species, actually drives beneficial remodelling. NOX4 activates two transcription factors, NRF2 and ATF4, which switch on protective genetic programmes. It also rewires the heart’s metabolism—changing how it uses fuel, builds structural components, and manages stress. These metabolic shifts may be the key to helping the heart adapt. This is fundamental science. The team aims to map exactly which metabolic pathways matter, how NOX4 controls them, and how to amplify that reprogramming for therapy. If they succeed, the result would be a completely new class of heart failure treatment—one that strengthens the heart’s own resilience rather than just blocking damage. Similar fundamental discoveries about metabolic reprogramming have already transformed cancer treatment; this work could do the same for heart disease.